Genetic factors contribute to patient-specific warfarin dose for Han Chinese.
about
Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysisEffect of genetic variants, especially CYP2C9 and VKORC1, on the pharmacology of warfarinGenetic factors associated with patient-specific warfarin dose in ethnic IndonesiansIn Silico Investigation of Cytochrome P450 2C9 in relation to Aging Using Traditional Chinese Medicine.A haplotype of CYP2C9 associated with warfarin sensitivity in mechanical heart valve replacement patients.CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacementA pharmacogenetics-based warfarin maintenance dosing algorithm from Northern Chinese patients.Warfarin dosage response related pharmacogenetics in Chinese population.Impact of polymorphisms of the GGCX gene on maintenance warfarin dose in Chinese populations: Systematic review and meta-analysisPolymorphisms in genes involved in the absorption, distribution, metabolism, and excretion of drugs in the Kazakhs of Kazakhstan.Genetic variation and haplotype structure of the gene Vitamin K epoxide reductase complex, subunit 1 in the Tamilian population.The pharmacogenetics of the response to warfarin in Chinese.Frequency of Common VKORC1 Polymorphisms and Their Impact on Warfarin Dose Requirement in Pakistani Population.Frequency of Common CYP2C9 Polymorphisms and Their Impact on Warfarin Dose Requirement in Pakistani Population.New genetic variant that might improve warfarin dose prediction in African Americans.Validation of warfarin pharmacogenetic algorithms in 586 Han Chinese patients.Influence of ORM1 polymorphisms on the maintenance stable warfarin dosage.Impact of CYP2C9*3, VKORC1-1639, CYP4F2rs2108622 genetic polymorphism and clinical factors on warfarin maintenance dose in Han-Chinese patients.Genetic polymorphisms are associated with variations in warfarin maintenance dose in Han Chinese patients with venous thromboembolism.Proposal of pharmacogenetics-based warfarin dosing algorithm in Korean patients.ARMS test for diagnosis of CYP2C9 and VKORC1 mutation in patients with pulmonary embolism in Han Chinese.Effect of CYP2C9, VKORC1, CYP4F2 and GGCX genetic variants on warfarin maintenance dose and explicating a new pharmacogenetic algorithm in South Indian population.Vitamin K epoxide reductase complex 1 (VKORC1) haplotypes in healthy Hungarian and Roma population samples.Gamma-glutamyl carboxylase and its influence on warfarin dose.Effects of torsemide on pharmacodynamics and pharmacokinetics of warfarin in humans and rats.The influence of genetic polymorphisms and interacting drugs on initial response to warfarin in Chinese patients with heart valve replacement.Multiplex pyrosequencing method to determine CYP2C9*3, VKORC1*2, and CYP4F2*3 polymorphisms simultaneously: its application to a Korean population and comparisons with other ethnic groups.Variability of warfarin dose response associated with CYP2C9 and VKORC1 gene polymorphisms in Chinese patients.Pharmacogenomics Aspect of Warfarin TherapyEstablishment of a Han Chinese-specific pharmacogenetic-guided warfarin dosing algorithm
P2860
Q27002899-F16F8E5C-3706-419A-8EDA-EC7B55B167E8Q28276514-FE5EFA51-50B3-41A5-88E2-F680782DAA35Q31016306-373AD200-3539-4CB2-8601-F9FD3ADD563AQ33668052-B8B20C17-1423-4362-80DC-BAF9817E06C4Q34026245-8196A32F-3B34-4791-9739-D6B4E742F2D6Q34026257-4E78B563-C4FB-4C2A-BE82-D54156654CCBQ34050936-87DE4F26-5B9C-4F49-8F95-4F8DB65A04F0Q34977531-45859C03-FD3B-4580-A949-5DA1920B2435Q35757323-6FB446CE-E40D-45E5-9B3D-92627D9C33DDQ35898150-5D46528B-E115-47A2-8AA7-F547B426F46BQ36813817-AE3C5EEF-076B-4D5F-82B5-CC45217107E8Q37948863-99AE191D-6821-4142-BDF6-5C91786AC076Q39159490-31D0ED82-BC60-49A4-8499-4B57D9AC725AQ39676335-360C2256-2A1C-461C-AAF0-191C4B999415Q39846791-11806439-ECD7-4148-839F-F6D7A19F2C51Q40644723-E3B2DF82-34C2-4637-B779-AA086C2254F3Q42713959-D71BFE44-F470-46AB-B508-23B35073038AQ42718669-478311B2-B807-493F-8269-F81EFC4F4666Q42722363-99C45E60-5907-4118-B3D1-25C7666F6427Q42750392-5394DB42-C1BC-49D5-9927-30185C460954Q43217456-C19FCF08-1351-4ED1-A2ED-2ED39CA19A9AQ44495777-2A37B480-C459-4F9D-AC5A-6D5872AEBDD5Q45749835-77A238F9-0E74-45FD-BD9B-6AF8C3305C36Q49811574-B9E0BAC9-7D38-4D6B-AF23-2A06C3005475Q50849656-5ED23ECD-065B-4B2E-AA0F-0217B40EE19EQ53159003-E0E512FD-4113-4A5D-ADE4-A1CF59543D29Q53268012-1B80E4AA-D79D-4BEE-8DFE-B173FA7AEB3AQ54519534-E6852D9F-58A0-459F-B2F1-087B2BF1BA21Q57179825-7C5F9665-485F-45A3-876D-21D79130C95BQ58759165-30EE862D-5636-4615-8A1B-2F8120D97123
P2860
Genetic factors contribute to patient-specific warfarin dose for Han Chinese.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Genetic factors contribute to patient-specific warfarin dose for Han Chinese.
@ast
Genetic factors contribute to patient-specific warfarin dose for Han Chinese.
@en
type
label
Genetic factors contribute to patient-specific warfarin dose for Han Chinese.
@ast
Genetic factors contribute to patient-specific warfarin dose for Han Chinese.
@en
prefLabel
Genetic factors contribute to patient-specific warfarin dose for Han Chinese.
@ast
Genetic factors contribute to patient-specific warfarin dose for Han Chinese.
@en
P2093
P1433
P1476
Genetic factors contribute to patient-specific warfarin dose for Han Chinese.
@en
P2093
Guan-Sheng Wu
Hai-Tao Zhu
Hong-Lei Li
Madeline Wu
Qian-Su Chen
Sheng-Jun Ma
Ting-Liang Wang
Wen-Ye Tjong
P356
10.1016/J.CCA.2008.07.005
P577
2008-07-12T00:00:00Z